Pirenzepine
From Wikipedia, the free encyclopedia
 |
|
|
Pirenzepine
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | A02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C19H21N5O2 |
| Mol. mass | 351.403 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pirenzepine (markated by Merck Marker under the trade-name Gastrozepin) is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as Muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as aposed to fight-or-flight), the result being an increase in gastric motility and digestion. It doesn't have any central effects because it doesn't diffuse through the blood brain barrier.
Pirenzepine has been investigated for use in myopia control.[1]
[edit] References
- ^ Czepita D (2005). "Fundamentals of modern treatment of myopia". Ann Acad Med Stetin 51 (2): 5-9. PMID 16519089.
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
